Breakthrough Bone Regeneration Therapies

Zetagen’s multi-patented, ZetaMet™ technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Our goal is to help the hundreds of thousands of people diagnosed with metastatic bone cancers and millions of people needing osteologic intervention.

Latest News

Press Releases

Zetagen Therapeutics Awarded $2 Million USD Grant from the National Cancer Institute (NCI) for Phase 2 Study of ZetaMet™ for Treatment of Metastatic Bone Cancers

December 13, 2021 – (Syracuse, New York) – Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received a two year, $2 million USD grant from the National Cancer Institute of the National Institutes of Health (NIH).

ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers

December 1, 2021 – (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, today announced it has received Breakthrough Device designation from the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its ZetaMet™ technology.

Zetagen Therapeutics, Inc. Announces European Patent for the Treatment of Stimulating Bone Growth

April 28, 2021 – (Syracuse, New York) - Zetagen Therapeutics, Inc. a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions today announced that the European Patent Office issued Patent. No. 3148517 to the Company.
Read All News
What we do
For Our
Patients
Zetagen is focused on the 330,000 people in the United States and more globally, annually living with some form of bone metastases. We have created a series of novel therapies which address metastatic cancers at progressive stages. Our therapies are designed to suspend cancer, inhibit pain, and regenerate bone. These technologies from Zetagen are adjunctive to other cancer treatments and can be administered when the lesion is first detected via a minimally invasive out-patient procedure. Pre-clinical studies have shown the potential to reduce lesion size by 200% and improve mortality rates of 250%.
Discover More
0
k
Patients Annually Diagnosed with Breast Cancer
(1 out of 8 Women)
0
k
Patients Annually Diagnosed with Metastatic Lytic Bone Lesions
(Breast, Lung, Myeloma, and Prostate)
0
%
% of patients Develop Skeletal-Related Event (SRE) from Metastatic Lytic Bone Lesions
*References: Australia (nbcf.org.au) | Canada (cancer.ca) | USA (breastcancer.org, ncbi.nlm.nih.gov, sciencedirect.com)
Breakthrough Technology

For Bone Regeneration

The U.S Food and Drug Administration (FDA) has recognized Zetagen’s discoveries with multiple Breakthrough Device Designations. Zetagen discovered and patented the first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. The small molecule has been approved by the FDA since 1971. Our research scientists have discovered an entirely new pathway for this established molecule which, if proven successful in human clinical trials, could create a new treatment paradigm for patients living with metastatic bone lesions and other osteologic conditions.
Learn More